Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial
Digitale Self-Management-Plattform für erwachsene Asthma-Patient:innen: randomisierte Attention-Placebo-kontrollierte Studie
Journal of Medical Internet Research · 2024-04-29 · 26 · e50855
DOI: 10.2196/50855 ↗Auf einen Blick
In einer 8-wöchigen RCT verbesserte juli die Asthmakontrolle gegenüber einer App-Version mit eingeschränkter Funktionalität. Der Effekt war in der Per-Protocol-Analyse signifikant.
Fragestellung
Verbessert juli als Smartphone-Platform das Selbstmanagement und die Asthmakontrolle bei Erwachsenen mit Asthma im Vergleich zu einer Attention-Placebo-App?
Methode
Pragmatische, einblinde, randomisierte kontrollierte Studie; 1:1-Zuteilung; 8 Wochen; vollständig remote. Primär Per-Protocol, sekundär modifizierte ITT-Analyse.
Ergebnisse
411 randomisiert; 152 in der Per-Protocol-Analyse, 262 in der modifizierten ITT-Analyse. ACT nach 8 Wochen: 17,93 vs. 16,24; adjustierter Koeffizient 1,91 (95 %-KI 0,31–3,51; P=.02).
Einschränkungen
63 % Attrition zwischen Baseline und Woche 8; 63,7 % hatten die Woche-2-Bewertung abgeschlossen.
Schlussfolgerung der Autor:innen
Die Nutzung von juli war über 8 Wochen mit einer besseren Asthmakontrolle verbunden als die Nutzung einer Version mit eingeschränkter Funktionalität.
Kernaussagen
- ACT nach 8 Wochen höher unter juli als unter Kontrolle
- Adjustierter Koeffizient 1,91 (95 %-KI 0,31–3,51)
- 63 % Attrition zwischen Baseline und Woche 8
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Randomisierte kontrollierte Studie in Journal of Medical Internet Research, published online on 2024-04-29. Written by Aaron Kandola and 5 co-authors. Institution: Medical Research Council Unit of Lifelong Health and Aging, University College London, London, United Kingdom. Major MEDLINE topics: Asthma, Self-Management, Mobile Applications. Cited 18 times so far (Crossref); 45 references. The full text is freely available in PubMed Central. Funded by: Wellcome Trust, Medical Research Council.
Abstract (original language)
Background
Asthma is one of the most common chronic conditions worldwide, with a substantial individual and health care burden. Digital apps hold promise as a highly accessible, low-cost method of enhancing self-management in asthma, which is critical to effective asthma control.
Objective
We conducted a fully remote randomized controlled trial (RCT) to assess the efficacy of juli, a commercially available smartphone self-management platform for asthma.
Methods
We conducted a pragmatic single-blind, RCT of juli for asthma management. Our study included participants aged 18 years and older who self-identified as having asthma and had an Asthma Control Test (ACT) score of 19 or lower (indicating uncontrolled asthma) at the beginning of the trial. Participants were randomized (1:1 ratio) to receive juli for 8 weeks or a limited attention-placebo control version of the app. The primary outcome measure was the difference in ACT scores after 8 weeks. Secondary outcomes included remission (ACT score greater than 19), minimal clinically important difference (an improvement of 3 or more points on the ACT), worsening of asthma, and health-related quality of life. The primary analysis included participants using the app for 8 weeks (per-protocol analysis), and the secondary analysis used a modified intention-to-treat (ITT) analysis.
Results
We randomized 411 participants between May 2021 and April 2023: a total of 152 (37%) participants engaged with the app for 8 weeks and were included in the per-protocol analysis, and 262 (63.7%) participants completed the week-2 outcome assessment and were included in the modified ITT analysis. Total attrition between baseline and week 8 was 259 (63%) individuals. In the per-protocol analysis, the intervention group had a higher mean ACT score (17.93, SD 4.72) than the control group (16.24, SD 5.78) by week 8 (baseline adjusted coefficient 1.91, 95% CI 0.31-3.51; P=.02). Participants using juli had greater odds of achieving or exceeding the minimal clinically important difference at 8 weeks (adjusted odds ratio 2.38, 95% CI 1.20-4.70; P=.01). There were no between group differences in the other secondary outcomes at 8 weeks. The results from the modified ITT analyses were similar.
Conclusions
Users of juli had improved asthma symptom control over 8 weeks compared with users of a version of the app with limited functionality. These findings suggest that juli is an effective digital self-management platform that could augment existing care pathways for asthma. The retention of patients in RCTs and real-world use of digital health care apps is a major challenge. Trial Registration International Standard Randomised Controlled Trial Number (ISRCTN) registry ISRCTN87679686; https://www.isrctn.com/ISRCTN87679686
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Medical Research Council Unit of Lifelong Health and Aging, University College London, London, United Kingdom.
- juli Health, Hull, MA, United States.
- Division of Psychiatry, University College London, London, United Kingdom.
- Camden and Islington NHS Foundation Trust, London, United Kingdom.
ORCID profiles: Aaron Kandola, Kyra Edwards, Joris Straatman, Bettina Dührkoop, Bettina Hein, Joseph Hayes
Funding
- Wellcome Trust
- Medical Research Council
Cite
APA
Kandola, A., Edwards, K., Straatman, J., Dührkoop, B., Hein, B., & Hayes, J. (2024). Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial. Journal of Medical Internet Research, 26, e50855. https://doi.org/10.2196/50855
Vancouver
Kandola A, Edwards K, Straatman J, Dührkoop B, Hein B, Hayes J. Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial. Journal of Medical Internet Research. 2024;26:e50855. doi:10.2196/50855
BibTeX
@article{Kandola2024,
author = {Kandola, Aaron and Edwards, Kyra and Straatman, Joris and Dührkoop, Bettina and Hein, Bettina and Hayes, Joseph},
title = {Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial},
journal = {Journal of Medical Internet Research},
year = {2024},
volume = {26},
pages = {e50855},
doi = {10.2196/50855}
}
EUVIMED